Summary
Parvovirus B19 lytically infects erythroid progenitor cells and thereby causes cessation of erythropoiesis in infected individuals. Anemia develops only if red cell turnover is increased, as in patients with chronic hemolysis (transient aplastic crisis). In addition to transient marrow failure, B19 can cause chronic anemia and, rarely, pancytopenia in immunodeficient patients who are not able to mount an adequate immune response to clear the virus. Bone marrow transplantation, although causing significant immunosuppression, is rarely complicated by symptomatic B19 infection. This is probably due to effective passive immunotherapy by immunoglobulin infusions immediately after transplantation and early reconstitution of antibody responses after uncomplicated transplantation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson MJ, Higgins PG, Davis LR, et al. (1985) Experimental parvoviral infection in humans. J Infect Dis 152: 257–265
Bär BMAM, Santos GW, Donnenberg AD (1990) Reconstitution of antibody response after allogeneic bone marrow transplantation: effect of lymphocyte depletion by counterflow centrifugal elutriation on the expression of hemagglutinins. Blood 76: 1410–1418
Bartolomei Corsi O, Azzi A, Morfini M, Fanci R, Rossi Ferrini P (1988) Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 25: 165–170
Berns KI (1990) Parvovirus replication. Microbiol Rev 54: 316–329
Caillet-Fauquet P, Perros M, Brandenburger A, Spegelaere P, Rommelaere J (1990) Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding nonstructural proteins. EMBO J 9: 2989–2995
Cohen BJ, Buckley MM (1988) The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 25: 151–153
Cossart YE, Field AM, Cant B, Widdows D (1975) Parvoviruslike particles in human sera. Lancet 1: 72–73
Feder HM Jr, Anderson I (1989) Fifth disease. A brief review of infections in childhood, in adulthood, and pregnancy. Arch Intern Med 149: 2176–2178
Frickhofen N, Young NS (1989) Persistent parvovirus B19 infections in humans. Microb Pathog 7: 319–327
Frickhofen N, Abkowitz JL, Safford M, et al. (1990) Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus-1: a treatable cause of anemia in AIDS. Ann Intern Med 113: 926–933
Frickhofen N, Cohen B, Young NS, Heimpel H, Abkowitz JL (1991) Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Blood 78 [Suppl 1]: 366
Gmür JP, Burger J, Schaffner A, et al. (1990) Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 75: 290–295
Kajigaya S, Hujii H, Field A, et al. (1991) Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci USA 88: 4646–4650
Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS (1988) Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 2: 1159–1162
Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS (1989) Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 84: 1114–1123
Kurtzman GJ, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS (1989) Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 321: 519–523
Mortimer PP, Humphries RK, Moore JG, Purcell RH, Young NS (1983) A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 302: 426–429
Mortimer PP, Luban NL, Kelleher JF, Cohen BJ (1983) Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet 2: 482–484
Niitsu H, Takatsu H, Miura I, et al. (1990) Pure red cell aplasia induced by B19 parvovirus during allogeneic bone marrow transplantation. Rinsho Ketsueki 31: 1566–1571
Ozawa K, Kurtzman GJ, Young N (1987) Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood 70: 384–391
Ozawa K, Ayub J, Kajigaya S, Shimada T, Young N (1988) The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 620: 2884–2889
Serjeant GR, Topley JM, Mason K, et al. (1981) Outbreak of aplastic crises in sickle cell anaemia associated with parvoviruslike agent. Lancet 2: 595–597
Takahashi T, Ozawa K, Takahashi K, Asano S, Takaku F (1990) Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 75: 603–610
Weiland HT, Salimans MMM, Fibbe WE, Kluin PM, Cohen BJ (1989) Prolonged parvovirus B19 infection with severe anaemia in a bone marrow transplant recipient. Br J Haematol 79: 300
Williams MD, Cohen BJ, Beddall AC, Pasi KJ, Mortimer PP, Hill FG (1990) Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 58: 177–181
Woolf AD, Campion GV, Chishick A, et al. (1989) Clinical manifestations of human parvovirus B19 infection in adults. Arch Intern Med 149: 1153–1156
Yaegashi N, Shiraishi H, Takeshita T, Nakamura M, Yajima A, Sugamura K (1989) Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J Virol 63: 2422–2426
Young N, Harrison M, Moore J, Mortimer P, Humphries RK (1984) Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest 74: 2024–2032
Author information
Authors and Affiliations
Additional information
This work was supported by a grant from theDeutsche Forschungsgemeinschaft (Fr 673/3-1)
Rights and permissions
About this article
Cite this article
Frickhofen, N., Arnold, R., Hertenstein, B. et al. Parvovirus B19 infection and bone marrow transplantation. Ann Hematol 64 (Suppl 1), A121–A124 (1992). https://doi.org/10.1007/BF01715363
Issue Date:
DOI: https://doi.org/10.1007/BF01715363